Brief: Acadia Pharmaceuticals Announces FDA Approval Of DAYBUE STIX For Oral Solution, A New Powder Formulation Of Trofinetide For The Treatment Of Rett Syndrome
12/12/2025 13:02
Dec 12 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O: ACADIA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF DAYBUE® STIX (TROFINETIDE) FOR ORAL SOLUTION, A NEW POWDER FORMULATION OF TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME Source text: ID:nBw1JprCDa Further company coverage: ACAD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP